Navigation Links
Sorrento Therapeutics Completes Acquisition of Concortis Biosystems
Date:12/19/2013

uel our R&D pipeline over the long-term," said Henry Ji, Ph.D., President and CEO of Sorrento. "The successes of first-generation ADCs have paved a path for new conjugation technologies. Our ownership of each of the key components of an ADC – the antibody, conjugation chemistry, linkers, and toxins – gives us a distinct and unique advantage in the field."

About Sorrento Therapeutics, Inc.

Sorrento Therapeutics is an oncology company developing a deep pipeline of new product candidates for the treatment of cancer and associated pain. Sorrento is advancing Cynviloq, a next-generation paclitaxel, into a Phase 3 clinical trial via the abbreviated 505(b)(2) pathway. Sorrento is also developing Resiniferatoxin (RTX), a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the National Institutes of Health to treat terminal cancer patients suffering from intractable pain. The company has also developed a diverse library of fully functional monoclonal antibodies, complemented by a comprehensive ADC platform comprised of wholly owned conjugation chemistry, linkers and toxic payloads. Sorrento's multi-pronged approach to combating cancer with small molecules, antibodies, and ADCs provides optionality in addressing the complexity of cancer.

Forward-Looking Statements

This press release contains forward-looking statements under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected.  Forward-looking statements include statements about the potential for products to be successfully developed using the Concortis technologies; the synergies and prospects for a combined enterprise going forward, including the retention of key personnel; and the clinical development and commercial potential of conjugated antibodies that may be developed based on
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology
2. Sorrento Therapeutics Adopts Stockholder Rights Plan
3. Sorrento Therapeutics Enters into Antibody and Vaccine Development Alliance for the Prevention and Treatment of Obesity
4. Sorrento Therapeutics Announces Closing of Public Offering of Common Stock
5. Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
6. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
7. Sorrento Therapeutics Completes IgDraSol Merger
8. Sorrento Therapeutics to Present at Two Healthcare Conferences
9. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
10. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
11. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... CAMBRIDGE, Mass. , Sept. 29, ... Group, Inc. (KEW), a privately held oncology services ... companies to make KEW,s state-of-the-art diagnostic services available ... KEW is a privately held oncology services company ... empowering all oncologists to access and apply genomic ...
(Date:9/29/2014)... Novogen Ltd. (ASX: NRT, NASDAQ: NVGN ) CEO ... with ABC TV that was broadcast on Saturday September 27th ... following day on Weekend Breakfast. The interview concerned the Company,s ... in Australia for the treatment of ... The interview provides certain new information and is being announced ...
(Date:9/29/2014)... , Sept. 29, 2014  Lpath, Inc. ... in bioactive lipid-targeted therapeutics, announced today the closing ... offering.  As previously disclosed, Lpath sold 3,605,042 registered ... 3,605,042 unregistered shares of common stock in a ... $3.475 per share-and-warrant-share combination.  The warrants have an ...
Breaking Medicine Technology:Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists 2Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists 3Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists 4ABC TV Interview Discusses the Potential of Trilexium(TM) to Treat Brain Cancer 2ABC TV Interview Discusses the Potential of Trilexium(TM) to Treat Brain Cancer 3Lpath, Inc. Announces Closing of $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces Closing of $12.5 Million Registered Direct Offering 3
... PARK, Fla., Feb. 27, 2012 WHAT: Gearing up for its 2012 ... Fla., Transitions Optical, in conjunction with the Coconut Grove Chamber ... national travel expert Marybeth Bond, has listed the "Top 25 ... and is asking travel enthusiasts – tourists and Miami locals ...
... Calif., Feb. 27, 2012 Masimo (NASDAQ: MASI ) ... 24th Annual ROTH Conference at the Ritz Carlton Laguna Niguel in ... Pacific Time.  A live audiocast of the presentation will be available ... the audiocast will be available following the live presentation. ...
Cached Medicine Technology:Transitions Optical Kicks-Off 2012 Multi-City "Sightseeing City Tour" with Voting Contest for "Top 10 Sights to See" in Miami 2Masimo to Present at 24th Annual ROTH Conference 2Masimo to Present at 24th Annual ROTH Conference 3
(Date:9/30/2014)... Barbara Williamson shares her life story ... "An Extraordinary Life: Love, Sex and Commitment" . As ... of the highly successful and controversial Sandstone Retreat in ... the couple started what became known as the hub ... Retreat was outrageously popular, with a membership reaching 500 ...
(Date:9/30/2014)... September 30, 2014 Computer Resources ... solutions firm based in New York City, has ... Manage360° solution to transform, manage, and support the ... who is a leading provider of innovative services ... self sufficient. The contract will cover the ...
(Date:9/30/2014)... Bibliomotion is proud to announce the release ... Complex Social Age by Frank Guglielmo and ... the authors apply their leadership coaching experience to introduce Social ... actions, and behaviors that leaders must adopt in order to ... to read a review of The Social Leader in Dialogue ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 RBS Reputation Management ... service named ‘Remove Your Name’. , The service name ... reason behind giving the service this odd name, a management ... nothing odd in this name. We have named the service ... as organizations to get rid of all those posts which ...
(Date:9/30/2014)... 30, 2014 A trailblazer at heart, Dr. ... out upcoming medical breakthroughs in spine repairs. His newest ... in his patients in which he has implanted the ... components are state-of-the art and mimic normal human disc motion. ... also been proven to be an exceptional replacement device for ...
Breaking Medicine News(10 mins):Health News:The Autobiography "An Extraordinary Life: Love, Sex and Commitment" Embraces Healthy Sexual Behavior 2Health News:The Autobiography "An Extraordinary Life: Love, Sex and Commitment" Embraces Healthy Sexual Behavior 3Health News:CRA Awarded Managed Services Contract for Large NYC Nonprofit 2Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 2Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 3Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 4Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 5Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 6Health News:RBS Reputation Management Announces A New Service ‘Remove Your Name’ 2
... FL, June 30, 2010 The Florida Biomedical Research ... to three scientists from the Florida campus of The ... to Glenn Micalizio, an associate professor in the Scripps ... five years; Thomas Bannister, assistant professor of medicinal chemistry ...
... Scientists at the Stanford University School of Medicine ... finding is significant because the existence of such a ... source of debate. It may also explain why current ... human patients. "These cells lack the traditional ...
... By Randy Dotinga HealthDay Reporter , WEDNESDAY, June ... daughter avoid dementia much later on in life, a new study ... to play. Canadian researchers believe they,ve found a link between ... senior years. The study doesn,t definitively prove that exercise lowers ...
... People who care about improving the environment in life may ... Europe have developed two new and unusual methods of body ... compost method that turns bodies into soil that could ... the topic of an article in the current issue of ...
... Glinert and Jon Schommer, the associate head of the ... University of Minnesota, have examined the corporate websites dedicated ... startling lack of consistency in an industry where advertising ... (FDA). "Communicating via a website is common ...
... ... ... -- Practical solutions and protocols will once again be exchanged at Cambridge Healthtech ... Boston. The four meetings comprising the event (Optimizing Cell Culture Technology, Affinity ...
Cached Medicine News:Health News:Scripps Research scientists share $2 million in Florida state research grants 2Health News:Melanoma-initiating cell identified by Stanford scientists 2Health News:Melanoma-initiating cell identified by Stanford scientists 3Health News:Melanoma-initiating cell identified by Stanford scientists 4Health News:Exercise May Guard Girls Against Dementia in Senior Years 2Health News:Linguistics professor examines manufacturers' prescription drug websites 2Health News:Cambridge Healthtech Institute Announces its Second Annual "The Bioprocessing Summit" 2Health News:Cambridge Healthtech Institute Announces its Second Annual "The Bioprocessing Summit" 3
... The PRO6000 power supply ... Thermo's power supply product offering. ... proteomic and genomic electrophoresis. This ... to proteomic applications such as ...
... voltage power supply, the 105 is very simple ... switch control the output, which is variable in ... two-position switch toggles the bright LED display from ... is equipped with an over current detector for ...
... supply is capable of producing up to 250 ... operates in constant voltage or constant current with ... over from one mode of operation to the ... A dual function, auto ranging 24-hour up/down ...
... is designed for horizontal and vertical gel ... be accomplished. In this power supply model, ... current or constant voltage. Four sets of ... connected simultaneously. This power supply's light, compact ...
Medicine Products: